SREBF2 and Alzheimer disease: Given that SREBP-2 nuclear activity in the CNS is elevated in AD (86), driving a feed-forward positive regulatory loop with miR-33, and that ORP6 is a major miR-33 target, reduced ORP6 expression in AD might be due to elevated SREBP-2/miR-33 expression.